Category:Antineoplastic monoclonal antibodies
Jump to navigation
Jump to search
A class of monoclonal antibodies with a cell-killing intended effect, generally either through disruption of cell signaling pathways leading to apoptosis, antibody-dependent cellular cytotoxicity (ADCC), or a combination of mechanisms.
Subcategories
This category has the following 41 subcategories, out of 41 total.
A
- Anti-BCMA antibodies
- Anti-c-Met antibodies
- Anti-CCR4 antibodies
- Anti-CD19 antibodies
- Anti-CD194 antibodies
- Anti-CD20 antibodies
- Anti-CD22 antibodies
- Anti-CD27 antibodies
- Anti-CD30 antibodies
- Anti-CD33 antibodies
- Anti-CD37 antibodies
- Anti-CD38 antibodies
- Anti-CD47 antibodies
- Anti-CD52 antibodies
- Anti-CD79B antibodies
- Anti-CLDN18.2 antibodies
- Anti-DKK1 antibodies
- Anti-EGFR antibodies
- Anti-FOLR1 antibodies
- Anti-GD2 antibodies
- Anti-GP-3 antibodies
- Anti-GPRC5D antibodies
- Anti-HER2 antibodies
- Anti-HGF antibodies
- Anti-HGFR antibodies
- Anti-IGF-1R antibodies
- Anti-mesothelin antibodies
- Anti-nectin-4 antibodies
- Anti-P-selectin antibodies
- Anti-PDGFR antibodies
- Anti-RANKL antibodies
- Anti-SLAMF7 antibodies
- Anti-TACSTD2 antibodies
- Anti-TF antibodies
- Anti-TRAIL-R1 antibodies
- Anti-TRAIL-R2 antibodies
- Anti-VEGF antibodies
- Anti-VEGFR antibodies
- Antibody-drug conjugates